Will active surveillance for clinically localized prostate cancer survive in the era of individualized medicine?

Abstract

The challenge for the next few years will be to individualize prostate cancer treatment and to determine whether or not a cancer will be lethal based on molecular characteristics at the time of diagnosis. In this view, the need for active treatment would represent a failure of any conservative approach.